| 摘要 |
<p>The invention relates to a new use of growth hormone, wherein growth hormone, for instance recombinant growth hormone, preferably human recombinant growth hormone, is used to manufacture a pharmaceutical preparation to treat patients with a low triiodothyronine level. A low triiodothyronine level can be the result of the low T3 syndrome as described in the literature. The low T3 syndrome in a patient can be caused by a large number of clinical conditions, which can be both physical and mental. The use of medicines can also cause the low T3 syndrome. According to the invention one or more thyroid hormones and/or anabolic steroids can be administered simultaneously with growth hormone.</p> |
